BALTIMORE, MD--(Marketwired - Apr 30, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that the trend toward a broader engagement of medical marijuana research is clearly moving ahead and could have a material impact on Nuvilex Inc. (
There are some startling statistics that illustrate the need for major change in how oncology treatments are performed, which also happens to sit firmly in Nuvilex's wheelhouse.
According to a study by the University of Chicago, one-third of chemotherapies are used off-label. In other words, 1 in 3 chemotherapy treatments is used to treat cancers in which the FDA never approved to treat. Such steps can jeopardize the health and safety of the cancer patients and cannot be properly measured by any risk/benefit analysis. An estimated $12 billion was spent on chemotherapies in 2010, with up to $4 billion on off-label use. Clearly, as the numbers bear out, physicians are scrambling to seek complementary alternatives to be used in conjunction with or instead of FDA-approved therapies that may not be working alone.
Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., builds upon the Company's many years of experience in developing "all-natural" products for various uses by studying the medical applications of marijuana (Cannabis sativa) and developing treatments for serious human diseases. The components of marijuana that have shown medical activity are broadly known as "cannabinoids." In a number of studies, cannabinoids have demonstrated an ability to act as an anticancer agent.
Leveraging the use of Nuvilex's successful live cell-encapsulation technology to treat certain cancers in clinical trials and other tests, the Company's efforts are targeted towards developing treatments for some of the most difficult-to-treat forms of cancer. These include brain tumors and pancreatic cancer.
As the public clamors for better cancer treatment options, Nuvilex (
To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com .
About Nuvilex, Inc. (
Goldman Small Cap Research Rob Goldman Analyst 410-609-7100 rob@goldmanresearch.com
